SEC Form 4 · accession 0001209191-18-003006
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Apelian
Officer — COO and Ex. Medical Officer · Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.70 | Jan 5, 2018 | A | 150,000 | A | — | Jan 4, 2028 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option vests as follows: 25% of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of January 3, 2018, with the remaining shares to vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.